Efficacy of Dual-Wavelength Light-Emitting Diode Phototherapy for Chronic External Otitis: A Randomized Controlled Pilot Study
Article information
Abstract
Background and Objectives
Chronic external otitis (CEO) is a persistent inflammatory condition of the external auditory canal characterized by pruritus, otalgia, and otorrhea and is often difficult to treat. This study evaluated the clinical efficacy and safety of a novel portable dual-wavelength light-emitting diode (LED) phototherapy device at wavelengths of 660 and 940 nm.
Subjects and Methods
This prospective, randomized, controlled pilot study was conducted at a tertiary hospital between August and November 2024. Twenty-one adults with CEO persisting for more than 1 month were randomly assigned to three groups (n=7 per group). Randomization was performed using a computer-generated block randomization sequence. Group 1 received LED phototherapy alone, Group 2 received topical ofloxacin alone, and Group 3 received combined LED phototherapy and antibiotic therapy for 2 weeks. Outcomes were evaluated at baseline and after treatment using otoscopic findings, pure-tone audiometry, and visual analog scale scores for pain and discomfort.
Results
All 21 participants completed the study. Otoscopic examination showed that Group 2 showed the highest resolution of otorrhea, with 75.0% complete resolution compared with 25.0% in Group 1 and 20.0% in Group 3 (p=0.194). No significant between-group differences were observed in erythema and edema. Regarding subjective symptoms, LED therapy (Groups 1 and 3) resulted in a marked improvement. Group 1 showed a significant reduction in discomfort from 7.00 to 3.00 (p<0.05), whereas Group 3 also showed a significant reduction from 6.43 to 2.14 (p<0.01). Group 2 had a substantially lower baseline pain score (0.60±1.34), thereby limiting meaningful comparison due to a floor effect. Pure-tone audiometry revealed no significant changes across treatment groups. No serious adverse events, photosensitivity reactions, or thermal injuries were observed.
Conclusions
This pilot study revealed that dual-wavelength LED phototherapy is safe and significantly reduces pain and discomfort in CEO, whereas topical antibiotics remain superior for otorrhea resolution. Collectively, LED phototherapy may serve as an adjunctive or alternative option, particularly for patients seeking non-antimicrobial treatment.
Introduction
Chronic external otitis (CEO) is a persistent inflammatory condition of the external auditory canal lasting more than one month, characterized by itching, pain, discharge, and discomfort that impair quality of life [1,2]. Affecting approximately 3%–5% of the population, CEO is clinically challenging because of its recurrent course and poor response to conventional treatments [3]. Management typically relies on topical antibiotics and corticosteroids, but long-term use is associated with antibiotic resistance, secondary fungal infections, skin atrophy, local adverse effects, and poor compliance [4,5]. The pathophysiology involves disruption of the cerumen barrier, altered skin pH, and impaired epithelial integrity, leading to chronic inflammation and bacterial colonization [6]. Current therapies mainly target microbial control and often fail to modulate the underlying inflammatory process, with prolonged treatment potentially promoting resistant organisms [7,8]. These limitations have driven interest in non-antibiotic therapeutic alternatives.
Low-level light therapy (LLLT), or photobiomodulation, is a non-invasive modality that modulates cellular activity through non-thermal light [9,10]. Its effects include enhanced mitochondrial adenosine triphosphate production and regulation of oxidative stress and inflammatory cytokines [11,12]. Red (660 nm) and near-infrared (940 nm) wavelengths have demonstrated anti-inflammatory, tissue-repair, and analgesic properties [13-17], suggesting potential benefit for inflammatory ear diseases. However, evidence for LLLT in CEO remains limited [18].
This pilot study aimed to evaluate the efficacy and safety of a portable dual-wavelength light-emitting diode (LED) phototherapy device for CEO, compared with conventional topical antibiotic therapy, and to assess its potential as monotherapy or combination treatment for reducing inflammation and improving patient comfort.
Subjects and Methods
Prospective, randomized controlled pilot study was conducted at tertiary hospital, from August to November 2024. Twenty-one patients aged 19 to 60 years with CEO were enrolled. CEO was defined as inflammation of the external auditory canal persisting for more than one month with inadequate response to previous conventional treatment. Inclusion criteria comprised age between 19 and 60 years, diagnosis of CEO confirmed by otoscopic examination, duration of symptoms exceeding one month, inadequate response to at least one course of conventional topical treatment, and ability to provide informed consent and comply with study procedures. Exclusion criteria included known photosensitive skin conditions or diseases (including lupus and porphyria), presence of ear implants or medical devices in the ear, tympanic membrane perforation, history of ear surgery, history of infrared light therapy within the past month, acute furunculosis, concurrent participation in other clinical trials, pregnancy or lactation, and inability to comply with follow-up visits.
Randomization was performed using a computer-generated block randomization sequence (block size of 3) prepared by an independent statistician prior to study initiation. Sequential allocation was concealed in opaque, sealed envelopes opened only at the time of enrollment. But no stratification variables were used. Group 1 (LED phototherapy alone) consisted of seven patients who received dual-wavelength LED phototherapy using a portable ear-set device (Earnap, Healing Sound Co., Ltd.) delivering combined 660 nm red light and 940 nm near-infrared light. The treatment protocol consisted of 15-minute sessions administered four times daily for two weeks. Group 2 (topical antibiotics alone) comprised seven patients who received conventional topical antibiotic ear drops, specifically ofloxacin 0.3% otic solution administered as three to five drops twice daily for two weeks according to standard clinical practice. Group 3 (combination therapy) included seven patients who received both LED phototherapy according to the same protocol as Group 1 and topical antibiotic drops according to the same protocol as Group 2, administered concurrently.
LED phototherapy device
The LED phototherapy device utilized in this study was a portable, ear-tip headphone-style apparatus incorporating dual wavelengths (660 nm and 940 nm). The device employed nano-semiconductor technology for efficient energy delivery while preventing thermal injury. The ear-tip design allowed direct insertion into the external auditory canal, ensuring optimal light delivery to affected tissues. An integrated smartphone application enabled treatment compliance monitoring and symptom tracking. The device delivers 660 nm red light and 940 nm near-infrared light with 4-10 J/cm2 energy density and 100 mW/cm2 power density at the canal surface for 15-minute session (Supplementary Fig. 1 in the online-only Data Supplement). The device generates a mild, regulated thermal effect that aids in drying the external auditory canal, which is crucial in CEO management as a dry ear creates an unfavorable environment for microbial growth. The device’s design is based on a patented high-efficiency micro-LED technology (Korean Patent No. 10-2271031) utilizing insulator electron affinity principles for enhanced energy efficiency and safety [19].
Outcome measures
Primary outcomes included both objective and audiometric assessments. Otoscopic examination was performed at baseline and two weeks post-treatment using standardized procedures. External auditory canal appearance was assessed for the presence or absence of canal erythema, edema, discharge (otorrhea), and epithelial debris. Pure-tone audiometry measured hearing thresholds at baseline and post-treatment across standard frequencies including 250, 500, 1,000, 2,000, 4,000, and 8,000 Hz. The average of thresholds at 500, 1,000, 2,000, and 4,000 Hz was calculated to monitor for potential ototoxicity.
Secondary outcomes assessed subjective symptoms using validated instruments. Pain intensity was measured using a visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain) at baseline and post-treatment. Similarly, overall ear discomfort including itching, fullness, and irritation was assessed using a VAS from 0 (no discomfort) to 10 (severe discomfort) at baseline and post-treatment.
Safety monitoring was comprehensive throughout the study period. All adverse events were systematically recorded. Patients were specifically monitored for photosensitivity reactions, thermal burns, skin irritation, increased pain, or worsening of symptoms. Treatment compliance was monitored through device logs for LED groups and patient diaries for all participants.
Statistical analyses were performed using SPSS version 25.0 (IBM Corp.). Continuous variables are presented as mean± standard deviation. Between-group comparisons were conducted using one-way analysis of variance (ANOVA) or the Kruskal–Wallis test, and within-group comparisons using paired t-tests or Wilcoxon signed-rank tests, as appropriate. Categorical variables were analyzed using chi-square or Fisher’s exact tests, with p<0.05 considered significant. Given the pilot design, seven patients per group were enrolled to assess feasibility and preliminary efficacy; a formal power analysis indicated that approximately 200 patients would be required for a definitive trial.
The study protocol was approved by the Institutional Review Board of Yonsei University Health System (IRB No. 4-2024-0678) and registered with the Clinical Research Information Service (CRIS). All participants provided written informed consent before enrollment.
Results
Twenty-one patients with CEO were enrolled and randomly allocated to three treatment groups. Baseline demographic and clinical characteristics showed no statistically significant differences between groups. However, Group 2 (antibiotic alone) had notably lower baseline pain scores with a mean of 1.29±2.21 compared to Group 1 with 4.71±4.99 and Group 3 with 2.00±2.08, though this difference did not reach statistical significance (p>0.05). This baseline imbalance constitutes a floor effect limiting analgesic comparisons and is further discussed in the Limitations section.
Otoscopic examination revealed differential responses across treatment groups regarding objective inflammatory signs. Resolution of otorrhea (ear discharge) showed the most marked differences between treatments. Group 2 (topical antibiotics alone) demonstrated the most substantial reduction, with the number of cases decreasing from four (57.1%) at baseline to one (14.3%) post-treatment, representing a resolution rate of 75.0% (3/4 patients). In contrast, Group 1 showed a slight reduction from four cases to three (25.0% resolution rate), and Group 3 decreased from five cases to four (20.0% resolution rate). Improvement in edema was observed in all groups, with comparable resolution rates (Group 1: 50.0%, Group 2: 57.1%, Group 3: 50.0%; p=0.956). In the assessment of objective inflammatory signs, Group 2 (antibiotics alone) demonstrated the highest resolution rates for otorrhea (75.0%) and erythema (75.0%) compared to the LED treatment groups (Group 1: 25.0% and 25.0%; Group 3: 20.0% and 42.9%, respectively). However, these differences did not reach statistical significance (otorrhea: p=0.194; erythema: p=0.352), likely due to the limited sample size of the pilot study (Fig. 1).
Changes in objective inflammatory signs observed via otoscopic examination. The bar graphs display the number of patients presenting with otorrhea (A), erythema (B), and edema (C) at baseline and after the two-week treatment period. Group 2 (topical antibiotics) demonstrated the most substantial resolution in otorrhea, reducing from 4 cases to 1 (75.0% resolution), whereas LED-treated groups showed modest reductions. However, the differences between groups for erythema and edema resolution were not statistically significant (p>0.05). LED, light-emitting diode.
Pure-tone audiometry was conducted to assess the potential ototoxicity of the treatments by evaluating changes in hearing thresholds before and after the intervention. In the within-group analysis using paired t-tests, no statistically significant shifts in hearing thresholds were observed in any of the treatment arms, confirming the auditory safety of the procedures. Specifically, Group 1 (LED alone) showed a slight, non-significant improvement in mean hearing threshold from 36.6± 28.9 dB at baseline to 33.1±24.3 dB post-treatment (p=0.119). Similarly, Group 2 (antibiotics alone) and Group 3 (combination therapy) exhibited stable hearing thresholds with no significant changes; Group 2 moved from 39.9±14.4 dB to 42.0± 13.2 dB (p=0.283), and Group 3 changed from 32.1±19.8 dB to 33.3±20.2 dB (p=0.827). Furthermore, a one-way ANOVA performed to compare the magnitude of threshold changes (delta) across the three groups revealed no significant differences (F=0.81, p=0.459). These findings collectively demonstrate that dual-wavelength LED phototherapy, whether used as monotherapy or in combination with topical antibiotics, does not induce auditory impairment and maintains a safety profile comparable to conventional antibiotic therapy (Fig. 2).
Comparison of hearing thresholds pre- and post-treatment to assess safety. Mean pure-tone audiometry thresholds (average of 500, 1,000, 2,000, and 4,000 Hz) measured in decibels (dB HL) for Group 1 (LED alone), Group 2 (antibiotics alone), and Group 3 (combination therapy). No statistically significant shifts in hearing thresholds were observed within any group (p>0.05), and no significant differences were found between groups (p=0.459), confirming that the dual-wavelength LED therapy does not induce ototoxicity. Error bars represent standard deviation. LED, light-emitting diode.
Significant improvements in subjective symptoms were observed in the LED therapy groups. Group 1 (LED alone) demonstrated a notable reduction in pain VAS scores, decreasing from 4.71±3.25 at baseline to 1.86±2.27 post-treatment. This reduction showed marginal statistical significance (p=0.052). Group 3 (combination therapy) showed a slight decrease in pain VAS from 2.00±1.73 to 1.71±0.76, but this was not statistically significant (p=0.654). In contrast, Group 2 (antibiotics alone) showed no change in pain VAS scores, remaining at 0.60±1.34 at baseline and post-treatment (p>0.999). Importantly, lack of pain reduction in Group 2 should be interpreted floor effect rather than as evidence of analgesic inefficacy. Both LED-containing treatment groups showed significant reductions in discomfort VAS scores. Group 1 experienced a significant decrease in discomfort from 7.00±2.52 to 3.00± 2.16 (p=0.018). Group 3 achieved the greatest reduction in discomfort, decreasing from 6.43±2.76 to 2.14±1.57 (p=0.006), representing the most substantial symptomatic improvement among all groups. Group 2 showed a non-significant trend toward improvement in discomfort, changing from 4.80± 1.48 to 4.00±1.00 (p=0.178) (Fig. 3).
Changes in patient-reported subjective symptoms. A: Changes in pain VAS scores measured by visual analog scale (VAS, 0–10). B: Changes in overall ear discomfort VAS scores (VAS, 0–10) including itching and fullness. The LED-treated groups demonstrated marked improvement in symptoms; Group 1 showed a significant reduction in discomfort (p<0.05), and Group 3 showed the greatest reduction (p<0.01). In contrast, Group 2 (antibiotics) showed no significant changes in pain or discomfort scores (p>0.05), noting that Group 2 had notably lower baseline pain scores compared to other groups. Error bars indicate standard deviation. LED, lightemitting diode.
The safety profile was excellent, with no serious adverse events in any group. No photosensitivity, burns, or skin damage occurred in the LED groups, confirming device safety. Compliance exceeded 80% in Groups 1 and 3, indicating good acceptance. In Group 2, mild, transient stinging was reported by three patients and increased wetness by one, without treatment discontinuation.
Discussion
This pilot randomized controlled trial evaluated the efficacy of dual-wavelength LED phototherapy for CEO treatment and revealed a compelling dissociation between objective inflammatory resolution and subjective symptom relief.
The therapeutic effects of LED phototherapy in this study can be attributed to multiple photobiomodulation mechanisms at cellular and tissue levels [9,10]. Red light at 660 nm penetrates superficial tissues and modulates inflammatory cytokines, reducing TNF-α, IL-1β, and IL-6 while increasing anti-inflammatory IL-10, thereby targeting the inflammatory cascade of CEO [15]. It also stimulates fibroblast activity and promotes wound healing by enhancing tissue repair [13]. Nearinfrared light at 940 nm provides complementary effects through deeper tissue penetration, improving microcirculation and cellular energy metabolism via cytochrome c oxidase activation in mitochondria [11,16]. This enhances blood flow, supports epithelial regeneration, and facilitates inflammatory clearance. In addition, 940 nm light inhibits bradykinin release and nociceptor signaling, offering direct analgesic effects [17]. The dual-wavelength strategy integrates these mechanisms, combining surface anti-inflammatory and reparative effects with deeper metabolic enhancement and pain modulation. This synergy may explain the significant improvements in pain and discomfort observed, even when visible inflammatory changes were modest compared with antibiotic therapy.
A key finding of this study is the dissociation between two distinct therapeutic targets in CEO management. Topical antibiotics demonstrated clear superiority in controlling the infectious burden, achieving a 75% otorrhea resolution rate by directly reducing bacterial colonization and purulent discharge. This confirms that for patients presenting with significant purulent discharge and signs of active bacterial infection, antimicrobial therapy remains the appropriate first-line intervention. In contrast, LED photo-biomodulation appeared superior in modulating the inflammatory process and alleviating subjective symptoms—pain and discomfort—through mechanisms independent of direct antimicrobial activity. These two domains of treatment effect are not mutually exclusive but complementary: the optimal therapeutic strategy should be individualized based on the patient’s dominant clinical presentation. Patients with prominent discharge warrant antibiotic-first approaches, while those with pain- and discomfortdominant presentations with minimal discharge may derive greater benefit from LED therapy, either alone or in combination with antibiotics.
The discrepancy whereby antibiotics improved objective findings while LED therapy better relieved subjective symptoms may be explained by several factors. First, baseline pain scores were notably lower in Group 2 (0.60±1.34), creating a floor effect that limited observable improvement, whereas Groups 1 and 3 had greater room for change. Although not statistically significant, this imbalance may have influenced outcomes and should be addressed in future trials. Second, the treatments act through different mechanisms. Antibiotics primarily reduce bacterial load and discharge, explaining superior objective improvement, but do not directly affect pain pathways. In contrast, photobiomodulation modulates nociception and inflammatory mediators, leading to greater relief of pain and discomfort. Third, physical properties may also contribute. Liquid ear drops increase canal moisture, which can aggravate maceration and discomfort in chronic cases, as reflected by reports of wetness in Group 2. LED therapy, without adding moisture and with mild warming, may promote a drier canal environment, favorable for symptom relief in CEO. These findings suggest that treatment selection for CEO should be individualized based on the dominant clinical features and patient priorities rather than adopting a one-size-fits-all approach. For patients presenting with prominent discharge and objective inflammation as the primary concern, topical antibiotics remain an appropriate first-line therapy, as demonstrated by the marked discharge resolution (75.0%) in Group 2. The antimicrobial efficacy of antibiotics makes them particularly suitable for cases with heavy bacterial colonization and purulent otorrhea.
Conversely, LED phototherapy may be particularly beneficial for patients whose chief complaints are pain and discomfort with minimal discharge, offering symptom relief without the moisture burden of topical drops or concerns about antibiotic resistance. It may be especially useful in patients who have failed repeated antibiotic courses, those with predominantly inflammatory rather than infectious pathology, or individuals with antibiotic allergies or sensitivities. For more severe cases with both objective inflammation and marked symptoms, combination therapy showed potential, with the greatest statistical reduction in discomfort observed in Group 3 (p<0.01). However, the lack of significant pain improvement in the combination group suggests that concurrent liquid drops might attenuate some of the drying and analgesic benefits of LED therapy, or that the sample size was insufficient to detect a difference. This indicates the need for optimized combination protocols in future studies. The portable, home-use design of the LED device provides practical advantages, allowing convenient self-administration with good patient acceptance and high compliance. Together with its favorable safety profile, LED phototherapy represents a promising non-antibiotic option for symptom-oriented management of CEO, particularly in the context of growing antimicrobial resistance.
This study has several important limitations that must be acknowledged. First, the sample size was small (n=7 per group) owing to the pilot nature of the study, limiting statistical power and the generalizability of findings. All results should be interpreted as exploratory and hypothesis-generating; as noted in the Methods, a formal power analysis indicated that approximately 200 patients per arm would be required for a definitive confirmatory trial.
Second, despite computer-generated block randomization, a notable, though not statistically significant, baseline imbalance: Group 2 (antibiotic alone) had a near-zero mean pain VAS score (0.60±1.34) compared to Groups 1 and 3 (4.71±4.99 and 2.00±2.08, respectively).
In conclusion, this pilot randomized controlled study provides preliminary evidence that dual-wavelength LED phototherapy is safe and effectively reduces pain and discomfort in patients with CEO, while topical antibiotics demonstrate superior efficacy for objective otorrhea resolution. The findings suggest a complementary role for these two modalities, with treatment selection ideally guided by the patient’s dominant clinical features: antibiotic therapy for infection-predominant presentations with significant discharge, and LED phototherapy for symptom-predominant cases or as an adjunct in patients requiring long-term management or seeking alternatives to antimicrobial treatment.
Supplementary Materials
The online-only Data Supplement is available with this article at https://doi.org/10.7874/jao.2025.00871.
LED phototherapy. A: The LED phototherapy device. A portable, ear-tip headphone-style apparatus incorporating dual wavelengths (660 nm and 940 nm). B: The ear-tip design allowed direct insertion into the external auditory canal, ensuring optimal light delivery to affected tissues. The device delivers 660 nm red light and 940 nm near-infrared light with 4-10 J/cm2 energy density and 100 mW/cm2 power density at the canal surface for 15-minute session. LED, light-emitting diode.
Notes
Conflicts of Interest
The authors declare no conflicts of interest. The LED phototherapy device (Earnap, Healing Sound Co., Ltd., Seoul, Korea) was provided by the manufacturer for research purposes. The manufacturer had no role in study design, data collection, analysis, interpretation of results, or the decision to submit this manuscript for publication.
Author Contributions
Conceptualization: In Seok Moon. Data curation: Hee So Oh, Yun Kyung Yim. Formal analysis: Jeong Gum Lee. Funding acquisition: In Seok Moon. Investigation: In Seok Moon. Methodology: In Seok Moon. Project administration: Yun Kyung Yim. Supervision: In Seok Moon. Visualization: In Seok Moon. Writing—original draft: Jeong Gum Lee. Writing—review & editing: In Seok Moon. Approval of final manuscript: all authors.
Funding Statement
This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2022-0164 to I.S.Moon).
Acknowledgments
None
